Navigation Links
Orally Disintegrating Tablets and Thin Films Poised to See Strong Growth

FALLS CHURCH, Va., April 18, 2013 /PRNewswire/ -- Orally disintegrating tablets (ODTs) are coming into their own as mainstream pharmaceutical products.  Oral thin films (OTFs) have also come into strong prominence with the launch of Suboxone® (buprenorphine and naloxone) thin films demonstrating a huge potential for thin films in prescription products.  Statistics have shown that four out of five patients prefer orally disintegrating dosage forms over conventional solid oral dosages.  These factors, coupled with convenience and compliance advantages, have been (and will continue to) pave the way for ODT and OTF drug product growth.

During a recent interview with Technology Catalysts, Bob Duffy , Marketing Manager, Excipients & Drug Delivery Systems for SPI Pharma, a leading developer of ODT formulations using its Pharmaburst® technology, stated, "Due to advances in various drug delivery technologies, of which SPI's Pharmaburst direct-compression platform is a market leader, ODTs are no longer only for treating niche therapeutic areas.  With improvements in mouthfeel, disintegration time, and the ability to handle higher drug loading, the ODT market is on the verge of becoming mainstream in a variety of both prescription and OTC medications for treating pain, cough/cold, sleep disorders, GERD, and ED."

The OTF market has received a huge boost with the phenomenal success of Reckitt Benckiser's prescription thin film, Suboxone.  Suboxone scored sales of $513 million in 2011 and accounted for 96 percent of the OTF market.  The success of this product demonstrates an increasing consumer acceptance of thin films as well the ability of pharmaceutical companies to successfully use thin films for lifecycle management. 

The ODT and OTF markets are discussed in depth in Technology Catalysts International's latest report, Orally Disintegrating Tablet and Film Technologies – Seventh Edition.  Key information presented in the report includes the growing Japanese generic market, ODTs in the emerging markets, ODT and OTF pipeline analysis, innovative developments for delivery of proteins and peptides via ODTs and OTFs, and new nutraceutical thin film technologies and products.

The report also includes a market analysis of both ODTs and OTFs, sales of leading ODT products in 2010-2011, ODT brand erosion by generics, late stage prescription OTFs, and the sales potential for OTFs with key APIs.  Most importantly, the report contains screened and confirmed business and technology licensing opportunities from around the globe.

For complete report prospectus, pricing, and ordering information, please refer to:

About Technology Catalysts International:

Technology Catalysts International ("TCI") was founded in 1979 and provides consulting services in technology transfer and business research. The company specializes in technology licensing, technology assessment, and business intelligence. With a focus on pharmaceuticals, drug delivery, consumer healthcare, and advanced materials/processes, TCI's core consulting services are based on continuous monitoring of technological product development activities on a global basis.  TCI is headquartered in the US and has offices in the UK, Germany, Czech Republic, China, Korea, Japan, India, and Latin America.


Ajay Rastogi , Vice President
Technology Catalysts International
Telephone (703) 531-0257

SOURCE Technology Catalysts International
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Researchers Developing New Multiple Sclerosis Drug That Can Be Taken Orally
2. Mylan Launches Generic Version of Zyprexa® Tablets
3. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
4. Mylan Launches Generic Version of Plavix® Tablets
5. Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN)
6. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
7. Mylan Launches Generic Version of Viramune® Tablets
8. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
9. Jentadueto® (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with type 2 diabetes in Europe
10. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
11. Qualitest Receives FDA Approval for Levetiracetam Extended-Release Tablets, 500mg and 750mg
Post Your Comments:
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
Breaking Medicine News(10 mins):